YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
Key Highlights
- ➤AI Cancer Risk Assessment launches at US$10 promotional pricing, down from US$50
- ➤Assessment covers ten cancer types using a 52-question self-reported health survey
- ➤YD Bio (YDES) and EG BioMed’s assessment integrates with oncology laboratory and clinical services
- ➤YD Bio’s planned EG BioMed merger is anticipated to close in 2026, pending conditions and approvals
Expert Statements
Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio
“Understanding personal health risk factors can be a useful starting point for more informed discussions with healthcare professionals”
Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio
“This Assessment brings self-reported health information and published research together in a structured, personalized report. As part of our broader oncology platform, we believe it can help individuals better understand their risk factors and discuss appropriate next steps with their physicians.”
TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company (“EG BioMed”), officially launched the AI Cancer Risk Assessment (the “Assessment”), an online assessment that organizes an individual's self-reported health information into a personalized report in English and Chinese, covering ten cancer types with promotional pricing of US$10.
The Assessment is based on a 52-question health survey covering personal and family history, symptoms, lifestyle, environmental exposures and diet. The survey takes approximately ten minutes, with a personalized report generated shortly after completion. The report provides low, moderate or high risk stratification overall and for each of ten cancer types: breast, colorectal, lung, head and neck, pancreatic, liver, endometrial, prostate, biliary tract and gastric cancer. It identifies the factors that contributed most to each result, explains why they may be relevant, and includes screening information and personalized follow-up guidance. The Assessment requires no blood draw, imaging or a clinic visit.
Get started
Create a free account to read the full story.